In 2025, respiratory news highlighted advances in lung imaging, expanded support for pulmonary rehabilitation and promising ...

Interstitial lung disease (ILD) causes significant morbidity and mortality in patients with systemic autoimmune rheumatic diseases. Patients at high risk of ILD should be screened using ...

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

It can be a real pain in the neck. Rheumatoid arthritis, or RA, is an autoimmune disease in which the body mistakenly attacks ...

Imagine a world where breathing is a luxury and a cough marks the sound of an inner battle. Interstitial Lung Disease (ILD), a condition characterised by inflammation and fibrosis, is a major cause of ...

EULAR—The European Alliance of Associations for Rheumatology—has worked with the European Respiratory Society (ERS) to develop new clinical practice guidelines for interstitial lung disease (ILD) ...

The FDA has approved Jascayd (nerandomilast) as a treatment for a second lung disease, progressive pulmonary fibrosis, following the drug’s initial approval in October 2025 as a treatment for ...

Please provide your email address to receive an email when new articles are posted on . Patients with high apnea-hypopnea index scores had more high attenuation areas on CT and lower measures of lung ...

She was diagnosed with chronic lung disease in 2018.

EULAR - The European Alliance of Associations for Rheumatology - has worked with the European Respiratory Society (ERS) to develop new clinical practice guidelines for interstitial lung disease (ILD) ...